Aurobindo Pharma Shares Rise After FTC Approves Lannett Acquisition; Shares Trade Positive

Mumbai, June 19: Aurobindo Pharma Ltd said on Thursday that the U.S. Federal Trade Commission (FTC) has approved its proposed acquisition of Lannett Company LLC, clearing a key regulatory hurdle for the transaction.

The company said in an exchange filing that the approval relates to the acquisition announced on July 30, 2025, under which its wholly owned subsidiary, Aurobindo Pharma USA Inc., agreed to acquire a 100% membership interest in Lannett Company LLC from LANNETT SELLER HOLDCO, INC.

According to the disclosure, the FTC approval was received on June 19, 2026. Aurobindo Pharma said it expects the transaction to close before the end of the month, subject to customary closing procedures.

The acquisition is expected to strengthen Aurobindo Pharma’s presence in the U.S. pharmaceutical market by expanding its portfolio and commercial footprint through Lannett’s operations.

Stock Market Snapshot

Shares of Aurobindo Pharma traded in positive territory following the regulatory update, reflecting investor confidence in the progress of the acquisition.

As of 10:04 IST on June 19, 2026, Aurobindo Pharma shares were trading at ₹1,461.40, up ₹17.70, or 1.23%, from the previous close. The Aurobindo Pharma share price remained firm during the morning session as market participants assessed the significance of the FTC clearance and the likelihood of an imminent transaction close.

Regulatory approvals are often viewed as important milestones in cross-border acquisitions, reducing execution uncertainty and improving visibility on transaction timelines.

Company Background

Aurobindo Pharma is one of India’s largest pharmaceutical manufacturers, with operations spanning generic pharmaceuticals, active pharmaceutical ingredients (APIs), injectable products and specialty medicines.

The company has a significant presence in international markets, particularly the United States, which remains one of its largest revenue contributors. Through its subsidiaries, Aurobindo Pharma supplies a broad range of pharmaceutical products across multiple therapeutic categories.

The proposed acquisition of Lannett aligns with the company’s strategy of expanding its scale and product portfolio in the U.S. market.

Conclusion

The FTC approval marks a significant step toward completing Aurobindo Pharma’s acquisition of Lannett Company LLC. With the company expecting the transaction to close before month-end, investors will be watching for further updates on completion and potential integration plans.

The development removes a key regulatory obstacle and provides greater clarity on the timeline for one of Aurobindo Pharma’s notable overseas acquisitions.

Source:

• https://www.nseindia.com/get-quote/equity/AUROPHARMA/Aurobindo-Pharma-Limited
• https://nsearchives.nseindia.com/corporate/AUROPHARMA_19062026082621_LtrToSEsLannetUpdate19062026.pdf